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Introduction.
Neurotransmitter acetylcholine plays a fundamental role in central and peripheral nervous systems. Receptors of acetylcholine and proteins involved in its synthesis, secretion and degradation are established targets for pharmacological intervention (reviews (Kruse et al., 2014b; Soukup et al., 2017; Wess, 2004) ). Acetylcholine receptors that belong to the muscarinic class are G protein-coupled receptors (GPCRs), which are products of five genes (Chrm1-5). Muscarinic M1, M3 and M5 receptors are coupled to Gq and are known to mobilize free cytosolic Ca 2+ , whereas M2 and M4 receptors are coupled to Gi and down-regulate cAMP and regulate ion channels (Burford et al., 1995; Haga, 2013; Lechleiter et al., 1989) .
M3 receptor (M3R) is interesting in several ways. It is highly expressed in certain areas
of the nervous system and many endocrine and exocrine glands, playing a major role in hormone secretion (reviews: (Gautam et al., 2008; Kruse et al., 2014a) ). For example, it is responsible for cholinergic stimulation of insulin release (Kong and Tobin, 2011; Ruiz de Azua et al., 2012) . Other notable sites of M3R expression are the vascular endothelial cells and smooth muscle, such as the circular sphincter that closes the eye pupil
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phospholipid PIP2, leading to generation of second messengers IP3, DAG and Ca 2+ . Like many other GPCRs, M3R can also activate protein kinases via β-arrestin and participates in unique interactions with several other proteins (Budd et al., 2000; Kan et al., 2014; Simon et al., 2006; Wu et al., 2000) . Recently determined crystal structures of M3R and other muscarinic receptors characterized molecular architecture of these GPCRs, providing valuable insights into organization of their orthosteric binding sites (Kruse et al., 2012; Thal et al., 2016) .
The canonical paradigm in pharmacology postulates that an orthosteric ligand of a given receptor can be classified as a full or partial agonist, antagonist or inverse agonist and either activates or inhibits different signaling pathways mediated by the same receptor, to the same degree. In the past decade, this model has been rapidly evolving to accommodate the effects of many drugs that could not be described solely by these terms.
It has been observed that, as a single receptor couples to different signal transduction pathways, the degree to which each pathway is activated depends on the nature of the ligand bound to the receptor. Such phenomena are now referred to as functional selectivity, biased signaling or biased agonism. One of the first observations was an early finding that an antagonist of cholecystokinin receptor D-Tyr-Gly-[(Nle28,31,DTrp30)cholecystokinin-26-32]-phenethyl ester induces internalization of the receptor (i.e., stimulates β-arrestin pathway) without activation of a G protein (Roettger et al., 1997) . Another notable example is the stimulation of ERK activity via β-adrenergic receptors by such clinically important drugs as beta blockers propranolol and carvedilol (Azzi et al., 2003; Wisler et al., 2007) . Since those early observations, biased signaling
6 was reported for many receptors and ligands, thus becoming a general concept (Luttrell and Gesty-Palmer, 2010; Violin and Lefkowitz, 2007) .
Pilocarpine is an alkaloid that has been used to treat glaucoma since 1875. Historical studies of its agonistic effect on salivary secretion and antagonism toward atropine led to development of the basic concept of a drug receptor ("receptive substance") in 1905 (Maehle, 2004) . Since that time, numerous physiological and pharmacological studies established that pilocarpine selectively stimulates muscarinic receptors and has no nicotinic receptor action. Pilocarpine can activate all five muscarinic receptor subtypes, but most of the therapeutic effects of pilocarpine observed in humans are mediated by M3R. While there is a substantial number of publications describing effects of pilocarpine on M2R (e.g., (Gregory et al., 2010) , surprisingly few studies investigated its effects on M3R. Pilocarpine is generally classified as a full or partial agonist (Gurwitz et al., 1994; Karpinsky-Semper et al., 2014; Sykes et al., 2009) . In this paper, we report previously unappreciated aspects of pilocarpine pharmacology as it relates to M3R.
Whereas pilocarpine is a full agonist for M1R, we show that it can act as an antagonist for M3R under certain conditions. We also provide evidence for strong signaling bias of pilocarpine toward arrestin-Src pathway downstream of M3R.
8 HBSS or a stimulant in HBSS (at 2x final concentration) were added and images were taken at the indicated time points. After the images were displayed on a computer monitor, pupil diameter at each time point was compared to the value at time zero (100%).
Typically, the pupil of an enucleated eye remained wide open in the absence of a stimulus (pilocarpine or another agonist) for up to 90 minutes.
In situ RNA hybridization. Localization of Chrm3 messenger RNA was done using a custom fluorescence RNAscope probe (Advanced Cell Diagnostics). Experiments were performed with minor modifications of the manufacturer instructions, as descried earlier (Pronin et al., 2014) , using paraffin-embedded slices of the mouse eyes.
Free intracellular Ca 2+ assays. HEK293T, CHO or MIN6 cells were grown on poly-Llysine-coated 12-mm glass coverslips, washed with the culture medium and then incubated at 37°C in the culture medium containing 2 µM fura-2, AM for 60 minutes.
After loading fura-2, AM, the cells were kept at ambient temperature for no longer than 1.5 hours before imaging. Coverslips were secured in a flow chamber and mounted on the stage of a Nikon TE2000 inverted fluorescence microscope. The cells were continuously superfused with HBSS by gravity flow. To stimulate the cells, the flow was switched to agonist-containing HBSS for a time required by a specified experiment, and then back to the agonist-free buffer. Images were collected in real time every 5 seconds using a 20×
UV objective lens and recorded using MetaFluor software (Molecular Devices or M1R using FuGENE 6 transfection reagent. The next day cells were trypsinized and plated on poly-L-lysine-coated 12-mm glass coverslips. The day after, coverslips were secured in a flow chamber and mounted on the stage of a Nikon TE2000 inverted fluorescence microscope. The cells were continuously superfused by gravity flow with HBSS. To stimulate the cells, the flow was switched to agonist-containing HBSS for a specified time, and then changed back to the agonist-free buffer. Images were collected in real time every 5 seconds using a 20× objective lens and recorded using MetaFluor software (Molecular Devices). The excitation wavelength was 550 nm, with the emission set to 570 nm. Individual cells were selected as regions of interest for signal quantification. Traces shown here are averages of 10-20 cells from two to four independent experiments with three replicate coverslips per experiment. The peak response below the basal value was used for signal quantification.
MIN6 culture, stimulation and insulin ELISA. Cells were cultured in DMEM (Invitrogen, USA) with 25 mM glucose and 4 mM L-glutamine supplemented with 10% FBS, 100 µg/ml penicillin/100 µg/ml streptomycin, 50 µM β-mercaptoethanol, 1 mM sodium pyruvate and 10 mM Hepes pH 7.2. For a typical test, cells were suspended in DMEM, seeded at 3x10 5 per well in 24-well plates and grown to 80% confluency. Prior to application of stimulants, cells were pre-incubated with serum-and glucose-free DMEM for 1 h, then washed twice with KRB buffer containing 0.1% BSA, after which various agents required by the experiment were added in KRB. The supernatant from the stimulated cells was collected after 30 min at 37°C and stored frozen at -80°C until measurement of insulin. Samples were analyzed using mouse insulin "sandwich" ELISA This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Effect of pilocarpine on pupil constriction. As expected, application of pilocarpine caused constriction of the mouse eye pupil (miosis), and its full effect was comparable to that of another cholinergic agonist, CCh (Fig. 1A, B) (Atwood et al., 2011; Luo et al., 2008 µM ( Fig. 2A, B) . However, under the same conditions, pilocarpine fails to elicit any Ca 2+ response at concentrations up to 1 mM. To test if pilocarpine actually interacted with the receptor, we applied it together with CCh and found that pilocarpine completely blocked the CCh-induced signal (Fig. 2B) . Thus, we came to an unexpected conclusion that pilocarpine functions as an M3R antagonist by competitively inhibiting CCh-stimulated rise in cytoplasmic free Ca 2+ .
Next, to investigate if the apparent pilocarpine antagonism can be observed in an alternative system naturally expressing M3R, we examined mouse insulinoma MIN6
cells. The MIN6 cell line is commonly used as a model for studying pancreatic beta cell biology and known to secrete insulin in response to cholinergic stimulation (Selway et al., 2012; Weng et al., 1993) . As expected, application of Oxo-M resulted in a robust increase in free Ca 2+ ( Fig. 2C ) and the amount of insulin released to the medium ( Fig.   2D ). In contrast, pilocarpine failed to induce Ca 2+ response or insulin secretion.
Moreover, pilocarpine inhibited insulinotropic effect of Oxo-M (Fig. 2D ). Thus, pilocarpine acts as an M3R antagonist in MIN6 cells, similarly to its effect in HEK293T cells.
The antagonistic effect of pilocarpine toward M3R (Fig. 2 ) is surprising because this drug has been studied for decades both in vivo and in vitro and has been classified as an agonist. In vivo, the agonistic action of pilocarpine could be, in principle, explained by its effect on a different muscarinic receptor(s) along with M3R. However, numerous experiments with cells that do not have endogenous acetylcholine receptors show that, This article has not been copyedited and formatted. The final version may differ from this version. expressing M1R, whereas no effect on PIP2 in M3R-expressing cells was detected (Fig.   4C ). Furthermore, pilocarpine blocked CCh-stimulated PIP2 hydrolysis in M3R-overexpressing cells (Fig. 4D ). Since either an antagonist or partial agonist can occupy the orthosteric site of a GPCR, they would displace a full agonist and inhibit the functional response. In our experiments, pilocarpine reduced PIP2 hydrolysis below the detection level; in fact, its effect was indistinguishable from that of atropine (data not shown). Therefore, in the M3R-stimulated breakdown of PIP2 assay pilocarpine acts as an antagonist rather than a partial agonist. On the other hand, the increase in intracellular Ca 2+ was still observed when pilocarpine was added together with CCh ( Fig. 4E) ,
showing that in this assay pilocarpine acts as an agonist.
Taken together, our findings indicate that for M3R, pilocarpine can behave as either agonist or antagonist, depending on the expression level of the receptor and the downstream signaling. For M1R, pilocarpine is a full agonist regardless of the functional read-out.
To further investigate the relationship between PIP2 hydrolysis and Ca 2+ mobilization, we examined the effects of pilocarpine and CCh on M3R and M1R overexpressed in CHO-K1 cells under the same conditions (Fig. 5A, B (Evans et al., 1985) . A likely explanation is that at the endogenous level of M3R expression even high doses of agonist cause hydrolysis of only a small fraction of PIP2; this fraction is sufficient to stimulate the Ca 2+ release, but is too low to be detected using either radioactively labeled PIP2 precursor or the fluorescent PIP2 biosensor.
To test if the inability to stimulate PIP2 hydrolysis via overexpressed M3R was unique to pilocarpine, we performed pilot experiments with two other muscarinic agonists, oxotremorine (Oxo) and cevimeline. Like pilocarpine, they stimulated Ca 2+ responses (data not shown) and, similar to pilocarpine, neither Oxo nor cevimeline induced notable reduction in PIP2 (Fig. 7A) . Under identical conditions, Oxo-M, CCh and acetylcholine stimulated robust PIP2 hydrolysis. One obvious common feature in the latter three agonists is the quarternary amine of the choline moiety (Fig. 7B) . We speculate that this amine is the pharmacophore determining the ability of the drug to This article has not been copyedited and formatted. The final version may differ from this version. Fig. 8A, B) . However, the EC 50 for pilocarpine was about 10 times higher than that induced by Oxo-M, while the maximal level of pilocarpine-induced phosphorylation was only about 32% of that induced by Oxo-M. Since there is more than one signaling pathway that can couple M3R to ERK1/2 activation, we hypothesized that pilocarpinebound M3R could activate only one of these mechanisms, for example, β-arrestinmediated activation of Src kinase. We tested this idea by applying inhibitor of Src family kinases, 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine known as PP2 (Fig. 8C ) and found that it almost completely eliminated pilocarpine-induced ERK1/2 phosphorylation. In contrast, when MIN6 cells were stimulated with Oxo-M, more than 55% of ERK1/2 phosphorylation occurred even in the presence of the saturating (60 µM) concentration of PP2. This remaining ERK1/2 phosphorylation was almost completely blocked when an inhibitor of PKC (bisindolylmaleimide I, BIM) was included in the mix (Fig. 8D) . These results are consistent with the model (Fig. 9 ) that in This article has not been copyedited and formatted. The final version may differ from this version. MIN6 cells pilocarpine acts on M3R as a partial agonist that is biased toward a pathway sensitive to PP2, likely the β-arrestin-Src pathway.
Discussion.
Pilocarpine is a prototypical cholinergic drug present on the World Health Organization
List of Essential Medicines. Its ability to activate secretion by exocrine glands has been utilized for many decades to treat dry mouth and dry eye syndromes. Because it constricts smooth muscles in the eye releasing intraocular pressure, topical pilocarpine has been the treatment of choice for glaucoma. Early physiological experiments on pilocarpineatropine competition led to the development of one of the most important biochemical and pharmacological concepts, the concept of a drug receptor. Our paper reveals previously unappreciated aspects of pilocarpine pharmacology by showing that its effect on M3R cannot be described solely by full or partial agonism. According to our data, pilocarpine can also act as an antagonist or biased agonist for this muscarinic receptor depending on cellular environment and the read-out used to study molecular events downstream of M3R stimulation.
Importantly, we compared our M3R data with a similar Gq-coupled muscarinic receptor, M1R. Our results on M1R are consistent with the common knowledge that pilocarpine is a full muscarinic agonist. It is worth noting the multiplex technique that we developed to compare the two receptors. The M1R-and M3R-expressing cells were marked by co-transfection with red and green fluorescent proteins, which allowed us to This article has not been copyedited and formatted. The final version may differ from this version. examine the two cell populations simultaneously under identical conditions in real time (Fig. 3) . We recommend this simple method for comparing other receptors as well, particularly when the expected differences in the downstream signaling are small. For example, one could evaluate effects of drugs on closely related receptors, examine receptor mutants or the effects of co-expressed regulatory proteins.
In the Ca 2+ mobilization assay, we did not detect a significant difference between the responses of overexpressed M1R and M3R to either CCh or pilocarpine (Fig. 4 , Table   1 ). However, when we analyzed PIP2 hydrolysis in the same system, the difference between M1R and M3R was remarkable. For M1R, both CCh and pilocarpine acted as full agonists, eliciting a robust reduction in PIP2 level. M3R was also fully activated by
CCh, but with pilocarpine we did not detect any change in PIP2 signal (Fig. 4, 5 Our results show that even for such a well-known pharmaceutical as pilocarpine, the answer to the basic question of whether it is an agonist or antagonist could be different for the native versus the overexpressed form of the same receptor. Clearly, drugs and receptors that have been investigated less than pilocarpine and the muscarinic family must be analyzed in the native context.
Pilocarpine also failed to stimulate insulin secretion in MIN6 cells and blocked insulin responses elicited by Oxo-M, and so it works as an M3R antagonist in the pancreatic beta cell model. On the other hand, pilocarpine stimulates pupil constriction, and even though it is much less potent than other agonists, it is a full agonist in this system. It has an unusually high EC 50 that is three orders of magnitude above the reported K d of pilocarpine for M3R. Accordingly, the concentration of pilocarpine in eye drops is extremely high -2-4% (80-160 mM), and there is no explanation why the therapeutic dose is that high. Abnormally low ability of pilocarpine to cause activation of Gq was noticed earlier, when it was shown that pilocarpine-stimulated GTPγS binding in
M3R-transfected cells was several fold lower than with other agonists (Sykes et al., 2009).
Data on pilocarpine-stimulated generation of IP3 is controversial: some investigators
This article has not been copyedited and formatted. The final version may differ from this version. reported robust overexpressed M3R-mediated production (Ehlert et al., 1999) , others found pilocarpine to be a virtually ineffective stimulant of the overexpressed or endogenous M3R (Evans et al., 1985; Gurwitz et al., 1994) .
Together with the earlier observations, our results show that pilocarpine does not activate all signaling pathways triggered by M3R, which led us to propose that, unlike
CCh and Oxo-M, pilocarpine can act as a biased agonist (Fig. 9) . The following data in (Fig. 2) , and, thus, it acts as an antagonist.
The model presented in Figure 9 can explain much of our current data and possibly earlier observations (Gurwitz et al., 1994; Sykes et al., 2009 ). However, our study also exposed some phenomena where the underlying mechanisms are unclear. For example, it is puzzling why in the basic assay of pupil constriction pilocarpine works as a full agonist but requires an extremely high concentration. Classic pharmacology cannot explain the observed difference in the effects of 1 mM (30-fold above the Kd, ~99%
receptor occupancy) and 10 mM (300-fold above the Kd, ~99.9% receptor occupancy) (Fig 2) .
Another observation that we cannot yet explain is how pilocarpine can increase Ca 2+ via overexpressed M3R without inducing detectable PIP2 hydrolysis. In theory, Ca
2+
can come from a source that does not require IP3, but instead is activated, for example, by phosphorylation initiated by β-arrestin or another mechanism downstream of M3R.
Thus far, we found that in the absence of extracellular Ca 2+ pilocarpine can still induce Ca 2+ transients in CHO-K1 cells overexpressing M3R (Fig. 5C) , which points to an intracellular Ca 2+ source such as mitochondria. However, at the moment we favor a simpler explanation that is based on the assumption that very little IP3 is sufficient to trigger a full Ca 2+ release from the endoplasmic reticulum. Indeed, there is a significant
(1-2 orders of magnitude) shift to the right in the PIP2 compared to Ca 2+ dose-response curves measured with overexpressed M3 even with CCh (Fig. 5B) ; it is possible that for pilocarpine this difference is even bigger. This hypothesis suggests that some IP3 is generated locally, whereas the biosensor assay we use in this study can only detect changes in global PIP2. Imaging techniques such as TIRF (Wuttke et al., 2016 ) and a knockdown of potentially relevant signaling components can test these ideas in the future.
Our current work showed for the first time that pilocarpine acts on M3R not only as a full or partial agonist as it is known to act on other muscarinic receptors, but also as This article has not been copyedited and formatted. The final version may differ from this version. an antagonist, and a functionally selective ligand. Since these behaviors are particularly apparent with the endogenous M3R, we speculate that these properties might explain why pilocarpine has fewer side effects than CCh when used to treat dry mouth or glaucoma.
Understanding the structure-activity relationship in cholinergic drugs and receptors may expand their use for other diseases, such as diabetes, where biased signaling via M3R can improve the function and viability of beta cells.
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